George Pavlov bought $363K of MapLight Therapeutics (MPLT)
Executed Feb 18, disclosed Feb 20, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Feb 20), the stock returned -1.3% (delay-adjusted); from the execution session (Feb 18), -1.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
George Pavlov (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in MapLight Therapeutics, Inc. (MPLT). Across 1 priced purchase filing, the average 21-session return was -1.0% from execution and -1.3% from disclosure (delay-adjusted; derived). The largest single filing was $363K of MPLT (20,578 sh across 2 lots, as filed), executed Feb 18.
Healthcare · MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→